BARBOSA ANTONIO J. M.,BLOMGREN PETER A.,CURRIE KEVIN S.,KRISHNAMOORTHY RAVI,KROPF JEFFREY E.,LEE SEUNG H.,MITCHELL SCOTT A.,ORTWINE DANIEL,SCHMITT AARON C.,WANG XIAOJING,XU JIANJUN,YOUNG WENDY,ZHANG H
申请号：
NZ60400411
公开号：
NZ604004A
申请日:
2011.05.06
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
604004 Disclosed herein is a compound of formula I, wherein the variables are defined herein, and a pharmaceutical composition comprising said compound, a method of making said pharmaceutical composition and the use in the treatment of immune disorders, cancer, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders, and neurological disorders, and wherein the medicament mediates the Bruton&rsquo；s tyrosine kinase. Specific embodiments of the compound include the following: 5-[2-(hydroxymethyl)-3-[1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridin-3-yl ]phenyl] -8-thia-5-azatricyclo[7.4.0.02,7]trideca-1(9),2(7)-dien-6-one； 2-(3-(5-(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyidin-3-yl)-2-(hydroxymethyl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one； and 2-(6-fluoro-2-(hydroxymethyl)-3-(1-methyl-5-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one.
